The Life Sciences team advised Aclarion (Nasdaq: ACON, ACONW) on the closing of its registered direct offering of 506,803 shares of its common stock at a price per share of $9.25. All of the shares in the offering were sold by Aclarion. The gross proceeds to Aclarion from this offering were approximately $4.7 million, before deducting the placement agent’s fees and other offering expenses payable by Aclarion.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives MRS data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies.
The Goodwin team was led by Jennifer Porter, Justin Platt, Karin Yoo and Andrea Akinbola.
For more information on the offering, please read the press release.